In vitroSignificantly reduced IC-10 (p < 0.01) and IC-50 (p < 0.05)In vivoSpecific accumulation and prolonged retention at tumor sitesWhen combined with 8 Gy radiationTumor growth significantly inhibited (101% vs. 97.27% vs. 94.03% growth inhibition rate, p < 0.001)Survival markedly extended (165 ± 22 vs. 165 ± 22 (1) vs. 165 ± 22 (2) vs. 20.5 ± 8 days (3), p < 0.001)Anti-apoptotic response significantly reduced (6.2-fold increase in Bax/Bcl-2 ratio compared to radiation alone)Potent radiosensitizer—dose enhancement factor of 2.26 The gene discussed is BCL2; the disease is neoplasm.